

## ORIGINAL ARTICLE

# MENINGIOMA: A CLINICOPATHOLOGICAL EVALUATION

Nasrin Samadi & Seyed Ali Ahmadi

Department of Pathology, Sina Hospital, Hassan Abad Square,  
Tehran 11364, Iran

As yet no unifying grading system for meningiomas has been adopted. We evaluate epidemiologic factors of meningioma in Iran & degree of agreement between the two commonly used grading systems namely WHO (2000) and Mahmood systems. During a 6-year period 238 meningiomas were selected and reviewed by two independent pathologists using both grading systems. 205(86.1%) cases were benign, 19(8%) atypical and 14(5.9%) malignant. 181(18%) cases were primary and 51(27%) secondary; 35(68%) of the latter benign, 7(14%) atypical and 9(18%) malignant. All intraspinal meningiomas were benign. In benign cranial and spinal types female to male ratios were 1.9: 1 and 1.3: 1; while in atypical and malignant types were 1:1.4 and 1:3.1 respectively. Mean ages were 49.9 for benign, 41.1 for atypical and 50 for malignant types. The most frequent site of involvement in all grades of intracranial tumors was cerebral convexity (31.1%). The most common subtype was meningothelial (65.1%). Female preponderance seen in benign non-recurrent meningioma became increasingly less prominent and even reversed in recurrent, atypical and malignant forms. Benign recurrent tumors were similar to non-recurrent tumors microscopically. Kappa value comparing two grading systems was 0.947, so good agreements were found between Mahmood and WHO grading systems.

*Key words* : meningioma, brain tumor, intracranial, intraspinal, Mahmood grading system, WHO grading system


Submitted-20-02-2004, Accepted-03-12-06

### Introduction

Meningiomas are the most frequently encountered primary non-glial tumors of the central nervous system and constitute about 20% of all primary brain tumors. (1) They are benign in most instances and may be cured with gross total resection; however, approximately 9-22% of patients experience recurrence and rarely are they frankly malignant leading to metastasis. (2) Incidence of typical (benign) intracranial meningiomas in women exceeds that in men by a ratio of 3:2, in contrast atypical and malignant meningiomas are somewhat more frequent in males. (2) Intraspinal meningiomas has female to male ratio of more than cranial type; about 4:1 in some series. (3) The distribution of intracranial meningiomas is as following in most instances: cerebral convexity (35%), parasagittal (20%), sphenoid wing (20%), infra-tentorial (13%), interventricular (5%), tuberculum sellae (3%) and other sites (4%). (4) It has several subtypes including

meningotheliomatous, fibrous, transitional, secretory, Chordoid, clear cell, papillary, rhabdoid, psammomatous, microcystic, lymphoplasmic cell rich and metaplastic types. (5) The correlation between clinical behavior and histologic grading of meningiomas has been of much interest in recent years. Several grading systems have been used for meningioma. One of the most objective systems was introduced by Mahmood who modified the initial WHO grading system accomplished by numeric scoring. (6) In the recently revised WHO grading system (2000) comparing to its initial version some criteria has been changed. (7) Many factors considered to have prognostic significance such as sheeting, hypercellularity, cytologic atypia, increased mitotic index, necrosis, small cell change, brain invasion and elevated proliferative index of MIB-1. (4) Extent of resection is also a powerful prognostic indicator. In some areas such as skull base difficulties in achieving gross total resection exists, therefore the tumor site is also another important

**Figure 1 :** Some histologic features of different grades of meningioma: **1a** numerous mitotic figures seen in malignant meningioma. **1b** invasion of atypical meningioma (darker area) into the brain parenchyma (lighter area). **1c** characteristic whorls of benign meningothelial meningioma.



prognostic factor. (8) Meningioma may be the presenting feature of neurofibromatosis type 2 (NF2) particularly in childhood. (9) Finding of meningioma in an individual younger than 25 years of age should prompt an evaluation for an underlying genetic condition. (10) The aims of this study were: 9) - to take an estimate of meningioma in this region according to age, gender, location, histologic subtypes, and other clinical data b) - to evaluate the less well defined category of recurrent meningiomas with respect to demographic and histopathologic data i a c) -To compare the recent WHO grading system with Mahmood’s modified system.

In this retrospective study, 238 cases of meningiomas operated from 1997 to 2002 at Sina hospital Tehran were reviewed. Histological assessment and grading of tumors performed blindly according to both WHO 2000 schema and Mahmood’s modified WHO grading system by two independent pathologists. In Mahmood’s system, grading performed according to numeric scores based on 6 predetermined criteria (table 1). According to WHO 2000 schema the most important criteria for malignancy (anaplasia) are the number of mitotic figures per 10 high power microscopic fields (figure 1a) and loss of differentiation (table 2). Presence of brain invasion (figure 1b) or coexistence of 3 out of 5 certain histologic features also define a tumor as atypical (table 2). The usual

**Materials and methods**

*Table 1 : Mahmood’s modified grading system for meningioma (6)*

Score	Brain invasion	Mitosis	Nuclear pleomorphism	Necrosis*	Hypercellularity	Loss of architecture
0	Absent	none	Uniform, bland nuclei, no nucleoli	none	10 whorls fascicles/ HPF	none
1	Tumor pushing the brain without intervening meaning	1-1/10HPH	Occasional larger nuclei, 2-3 times larger with irregular contours	Rare, each involving less than 1/2 of HPF	10 whorls-fascicles/ HPF or increased cellularity in perivascular area	Incipient loss
2	Cords infiltrating the brain	3-4/10HPF	Many cells with large pale nuclei, small non prominent nucleoli	Frequent foci involving more than 1/2 but less than 1 HPF	Less defined, small, more closely packed whorls (up to 30/ HPF)	Involving 1-2 HPF
3		>5/10HPF	Most cells with nuclei, variable size, prominent nucleoli	Large confluent areas of necrosis >1 HPF	Densely crowded overlapping nuclei with loss of whorls	Involving more than 2 adjacent HPF

Score 0-4 =benign, Score 5-11 =atypical, Score>11 =malignant  
 \*In the absence of preoperative tumor embolization and radiation therapy

Table 2 : WHO histologic grading scheme for meningioma (2000) (7)

<p><b>Atypical meningioma:</b> any of the following three criteria:</p> <ol style="list-style-type: none"> <li>1- High mitotic index (<math>\geq 4</math> mitosis per 10 high power field or <math>\geq 2.5/\text{mm}^2</math>)</li> <li>2- Presence of brain invasion in a well-differentiated meningioma</li> <li>3- Presence of at least three of the following five features:                     <ul style="list-style-type: none"> <li>Sheeting (loss of lobular architecture)</li> <li>Hypercellularity</li> <li>Macronucleoli</li> <li>Small cell areas</li> <li>Spontaneous necrosis</li> </ul> </li> </ol> <p><b>Anaplastic meningioma:</b> Either of the following criteria</p> <ol style="list-style-type: none"> <li>1- Excessive mitotic activity (<math>\geq 20</math> mitoses per 10 high power fields or <math>\geq 12.5/\text{mm}^2</math>)</li> <li>2- Focal or diffuse loss of meningeothelial differentiation at the light microscopic level resulting in sarcoma, carcinoma, or melanoma-like appearance</li> </ol>
---

variants of meningioma (i.e. fibrous, meningeothelial and transitional) lacking the above criteria are grouped as benign (figure 1c). Chordoid and clear cell meningiomas graded as atypical and papillary and rhabdoid variants if presented focally graded as atypical and diffuse forms graded as malignant. Clinical data (age, sex, site of tumor, history of neurofibromatosis and presenting sign & symptoms) and history of recurrence till the end of 2003 were recorded and compared between groups. Two grading systems were compared and degree of agreement (kappa value) was determined. None of the patients had preoperative tumor embolization or

chemotherapy.

### Results

Overall comparison of two grading system considering all 3 groups; revealed good agreement (kappa = 0.947). The kappa values were 0.945 for benign, 0.908 for atypical and 1 for malignant meningiomas. Only 3 atypical meningiomas according to Mahmood’s system did not meet the WHO criteria for atypical grade. Due to good agreement of the two systems and more objectivity of the Mahmood’s system, we preferred to use it in

Table 3- Clinical data of study group

		Benign	Atypical	malignant	Total
<b>Number (%)</b>		205 (86.1)	19 (8)	14 (5.9)	238
<b>Mean age</b>		49.4	41.1	50	48.8
Sex	Female (%)	132 (92.3)	8 (5.6)	3 (2.1)	143
	Male (%)	73 (76.8)	11 (11.6)	11 (11.6)	95
Location	Intracranial (%)	189 (85.1)	19 (8.6)	14 (6.3)	222
	Intraspinal (%)	16 (100)	0	0	16
Recurrence	Primary (%)	170 (90.9)	12 (6.4)	5 (2.7)	187
	Secondary (%)	35 (68.6)	7 (13.7)	9 (17.7)	51
NF2* (%)		8 (88.9)	1 (11.1)	0	9

\*NF 2: neurofibromatosis type 2

Table 4 : Frequency of tumor location in study groups

Sites	Benign (%)	Atypical (%)	Malignant (%)
Cerebral convexity	68(31.1)	6(31.6)	7(50)
Sphenoid ridge	26(12)	4(21)	0
CP angle	25(11.5)	3(15.7)	2(14.3)
Parasagittal	19(8.7)	2(10.5)	2(14.3)
Olfactory groove	14(6.4)	1(5.3)	0
Parafalx	13(6)	1(5.3)	1(7.1)
Petroclivus	12(5.5)	1(5.3)	0
Orbital	7(3.2)	0	0
Cerebellum	3(1.4)	0	2(14.3)
Tentorial	3(1.4)	1(5.3)	0
Tuberculum sella	4(1.8)	0	0
Foramen magnum	3(1.4)	0	0
Anterior clinoidal	3(1.4)	0	0
Cavernous sinus	2(0.9)	0	0
Spinal	16(7.3)	0	0
Total	218	19	14

Note: In multiple meningiomas each tumor counted separately

this study. Of total 238 cases, 205(86.1%) were classified as benign, 19(8%) as atypical and 14(5.9%) as malignant. One hundred and eight seven (78.6%) cases were primary and 51(21.4%) cases were secondary. Distribution of patients' age, sex, tumor grade, location and other clinical data are presented in Table 3. Mean age for benign, atypical & malignant forms were 49.4, 41.1 and 50 respectively. There was no significant difference in the mean age between all grades although the mean age of malignancy was slightly higher. Female to male ratio in benign form was 1.81:1 but atypical and malignant variants were more common in men (p = 0.048 and 0.001) with female to male ratios of 1:1.3 in atypical and 1:3.7 in malignant forms. Considering all grades in all age groups there was

female predominance (female to male ratio 1.5:1); however under the age 40 this ratio was reverse (1:1.14). The most common site of involvement in all grades was cerebral convexity (Table 4).

The most common histologic subtypes were meningothelial (65.5%), transitional (17.2%) and fibrous (9.2%). The most common variants were metaplastic, chordoid, angiomatous, and lymphocyte-rich, each one constituting about 3% (Table 5).

Local bone invasion - although not a malignant feature per se - was seen in 26 patients (10.9%), 24 of them were in benign, one in atypical and one in malignant groups. 15 patients with benign primary meningioma 8.4% showed recurrence within the study period; 6 of them (40 %) were

Table 5 : Frequency of histopathologic subtypes of evaluated meningiomas

Subtypes	Number	Percent
Menigotheliomatous	155	65.1
Transitional	41	17.2
Fibrous	22	9.2
Metaplastic	3	1.3
Chordoid	3	1.3
Angiomatous	3	1.3
Lymphoplasmic cell rich	3	1.3
Clear cell	2	0.8
Psammomatous	2	0.8
Rhabdoid	2	0.8
Papillary	1	0.4
Microcystic	1	0.4
Secretory	0	0
<b>Total</b>	<b>238</b>	<b>100</b>

Table 6 : The most frequent presenting signs and symptoms

Signs and symptoms	Percent (%)	Signs and symptoms	Percent (%)
Headache and vomiting	46.4	Hearing loss	4.3
Visual problem	27.9	Sensory loss	3.4
Paresis	24	Personality change	3
Seizure	13.3	plegia	2.1
Proptosis	6	Speech disorder	1.3
Ataxia	5.2	Urinary incontinence	0.9
Cranial nerve palsy	4.7	dysphagia	0.9

male and 9(60%) were female. Mean age was 41.4. None of recurrent tumors revealed necrosis, mitosis or brain invasion. Thirteen of them were of benign histology in recurrences as their primaries; one of them was benign at first biopsy in 1998, atypical in first recurrence in 2001 and malignant in second recurrence in 2002. The other one was benign in 1998 and subsequently recurred as malignant in 2001. In recurrent tumors the most frequent sites were as the primaries. For 49.2% of the patients the tumor could not be resected totally due to location and local adhesions.

Sixteen patients (6.7%) had intraspinal meningiomas with mean age of 48.6 and female to male ratio of 1.3:1. All of them were benign with small size and no atypical features.

Of total 238 cases, 8 patients (3.4%) had multiple (2 to 3) benign meningiomas at presentation, with female to male ratio of 3:4 and mean age of 37 years. All of them were primary non-recurrent with no history of radiation and located in cerebral convexity, parasagittal, CP angle and petroclival region. Four out of them were known cases of neurofibromatosis type 2 (NF2). All of 9 patients (3.8 %) with NF2 included in this study had intracranial meningiomas. They were between 16 and 22 years old (mean = 18.67) and their tumors were located at cerebral convexity (6), CP angle (4), parasagittal (1), parafalx (1), sphenoid ridge (1) and orbital region (1). Eight of them were male with benign meningioma and the only 1 female had atypical brain-invasive meningioma. Four NF2 patients (44%) had multiple meningiomas. Two NF2 patients (22%) showed histologically benign recurrences in the study period at the same place and one of them had schwannoma of CP angle at the same time.

One patient (male 33 years-old) had tuberous sclerosis syndrome with 2 tumor types (meningioma and low grade astrocytoma) at the same time.

The most frequent presenting symptoms and signs were headache and vomiting (46.4%), visual

problems (27.9%), paresis (24%), seizure (13.3%) and proptosis (6%).(Table 6) In two patients CT scan performed for evaluation of head trauma incidentally found the tumor.

### Discussion

Meningiomas as brain tumors have been recognized for nearly 200 years. (11) Initially all of them were considered benign. Recognition of their recurrent and malignant potential has encouraged some authors to classify them according to their histology. Despite introduction of new subtypes in WHO grading system such as clear cell and Chordoid (assumed as atypical) and rhabdoid (assumed as malignant); disagreement with Mahmood’s system was observed only in 3 cases that had mild nuclear pleomorphism taking them to “atypical” group of Mahmood’s system while according to WHO system which considers only prominent nucleoli as important, these tumors were classified as “benign”.

The relative ratios of benign, atypical and malignant tumors in this study were about 14.3:1.3:1 respectively (Table 3). This is similar to another study<sup>2</sup> indicating the ratio of 16:2:1.

In our study female preponderance (1.3:1) was less obvious in spinal meningiomas compared to others (4:1). (3) This may be due to different genetic, environmental or other factors. In our study female predominance could be seen after 4<sup>th</sup> decade while in another report it was seen after 5<sup>th</sup> decade. (4) In atypical and anaplastic meningiomas we found obvious male predominance. This correlates with the study of Perry et al (12) and may indicate male sex as a negative prognostic factor. Perry also indicated that patients younger than 40 years had higher likelihood of recurrence independent of sex, grade or extent or resection; however; we found no significant age difference between recurrent and non-recurrent tumors.

Reportedly 4-15% of patients experience

recurrence due to unclear mechanisms that may include continued proliferation of residual tumor cells left behind at surgery, other factors such as tumor proliferative activity and vascular endothelial growth factor (VEGF) (8, 13) or multicentric tumors (tumor diathesis). In our study period recurrence rate was about 8.4% occurring 1 to 6 years following surgery; more than half of them recurred after apparently gross total resection, although in less than half of them it may also have been occurred due to incomplete resection. In recurrent group female to male ratio was 1.5:1 that was slightly lower than non-recurrent group; However; no significant difference was identified in routine histopathologic indices, age and involved sites compared to non-recurrent group.

The most common sites of involvement in our intracranial meningiomas were compatible with most previous studies i.e., cerebral convexity followed by sphenoid wing, CP angle, parasagittal region, olfactory groove, parafalcine, petroclivus and other sites. (4, 8)

About 3.3% of our cases were multiple, all of them with benign histology and half of them occurring in NF2 patients. In another reference its incidence was about 1-6% (14). It may be related to neurofibromatosis 2 or radiation (5). Rare instances of multiple meningiomas without vestibular schwannoma segregating as an autosomal dominant disorder have also been reported(15). In many instances however; no obvious etiology can be identified. (2)

Approximately half of individuals with NF2 develop meningiomas(16). As in our study most of NF2 meningiomas are intracranial; however, spinal meningiomas may also occur(17). In our NF2 patients the most common sites and type were cerebral convexity followed by skull base and meningothelial type but in other reports skull base is less frequent and they are usually of fibroblastic type. (18)

It should be mentioned that our limited study interval and limited numbers of intraspinal and rare subtypes of intracranial cases may necessitate more extended population studies and longer follow up periods to validate these results.

## Conclusion

In this study the prevalence of tumor location, histologic subtypes and grades as well as age and sex distribution were similar to other studies. When recurrent tumors compared to non-recurrents we

found no difference in age, site predilection and routine histologic difference. Compared to cranial tumors, spinal tumors showed less obvious female preponderance, lower recurrence rates and no atypicality or malignancy. In NF2 patients we found strict male preponderance (F:M ratio of 1:7.7), more common recurrence rate and tumor multiplicity. Finally in 238 cases of meningiomas studied, WHO and Mahmood grading systems had agreement in 235 cases which indicates excellent concordance rate ( $k = 0.947$ ).

## Corresponding Author :

Dr. Nasrin Samadi MD,  
Resident of Pathology, Department of Pathology,  
Sina Hospital, School of Medicine, Tehran  
University of Medical Sciences ; Department of  
Pathology, Sina Hospital, Hassan Abad Square,  
Tehran 11364, IRAN

**Tel:** +9821-66702051 **Fax:** +9821-66716545

**Email:** [nasrinmd\\_73@yahoo.com](mailto:nasrinmd_73@yahoo.com)

## References

1. Beatriz M, Lopes S, Horten BC, central nervous system tumors: meningiomas, In Weidner N, Cote RJ, Suster S, Weiss LM (editors) "modern surgical pathology" 1<sup>st</sup> ed, Philadelphia: Saunders 2003, vol 2, p:2091-2094
2. Burger P, Scheithauer BW, Vogel FC. Intracranial meninges, In : Surgical pathology of nervous system and its coverings. 4<sup>th</sup> ed. Philadelphia, Churchill Livingstone; 2002. p: 49-71
3. Burger P, Scheithauer BW, Vogel FC .Spinal meninges, spinal nerve roots and spinal cord, In : Surgical pathology of nervous system and its coverings.4<sup>th</sup> ed. Philadelphia, Churchill Livingstone; 2002. p: 527-531
4. Haddad GF, Al-Mefty O, Aboulrauf SI, meningiomas, In Winn HR "Youmans neurological surgery" 5<sup>th</sup> ed, Philadelphia; Saunders, 2004, p:1099-1131
5. Rosenblum M K, Bilbao JM, Ang LC: neuromuscular System: meningiomas In Rosai & Ackerman's surgical pathology. Volume1. 9<sup>th</sup> edition. Edited by Rosai J. Philadelphia: Mosby; 2004, p: 2564-2572
6. Mahmood A, Caccamo DV, Tomecec FJ, Malik GM. Atypical and malignant meningiomas: A clinicopathologic review. *Neurosurg* 1993; **33**: 955-63
7. Perry A, Scheithauer B, Stafford S, Lohse CM, Wollan PC, Malignancy in meningiomas a clinicopathologic study of 116 patients, with grading implications, *Cancer* 1999; **85**: 2046-56

8. Ming-Tak Ho D, Hsu CY, Ting LT, Chiang H, Histopathology and MIB-1 labeling index predicted recurrence of meningiomas, a proposal of diagnostic criteria for patients with atypical meningioma, *Cancer* 2002; **94**:1537-47
9. Perry A, Giannini C, Raghavan R, Scheithauer BW, Banerjee R, Margraf L, Bowers DC, Lytle RA, Newsham IF, Gutmann DH Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. *J Neuropathol Exp Neurol* 2001; **60**: 994-1003
10. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R, A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. *J Med Genet* 1992; **29**: 841-6
11. Joseph E, Sandhyamani S, Rao MB, Nair S, Radhakrishnan VV, Atypical meningioma: A clinicopathologic analysis, *Neurol India* 2000; **48**: 338-42
12. Perry A, Stafford S, Scheithauer B, Bernard W, Suman VJ. Meningioma grading: an analysis of histopathologic parameters. *Am J Surg Pathol*; 1997, **21**(12): 1445-65
13. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K, recurrence of meningiomas: influence of vascular endothelial growth factor expression, *Cancer* 2000; **89**:1102-10
14. Mckeever PE. The brain, Spinal cord and meninges. In: Sternberg SS, Antonioli DA, Carter SE, Oberman HA. Diagnostic surgical pathology .3<sup>rd</sup> ed. USA; 1999, p: 438-445
15. Maxwell M, Shih SD, Galanopoulos T, Hedley-Whyte ET, Cosgrove GR ,Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases. *J Neurosurg* 1998; Vol; 2-9
16. Perry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. *Am J Med Genet* 1994; **52**: 450-61
17. Argenyi ZB, Thieberg MD, Hayes CM, Whitaker DC. Primary cutaneous meningioma associated with von Recklinghausen's disease. *J Cutan Pathol* 1994; **21**: 549-56
18. Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Lekanne Dit Deprez R, Zwarthoff E NF2 status of meningiomas is associated with tumor localization and histology. *J Pathol* 2001; **194**: 367-72